1,25-Dihydroxyvitamin D3 Inhibits the RANKL Pathway and Impacts on the Production of Pathway-Associated Cytokines in Early Rheumatoid Arthritis

Table 5

The impact of 1,25(OH)₂D₃ and MTX cotreatment on inflammation-related cytokines in the RA and healthy control group.

	RANKL; (pmol/L)	OPG; (pmol/L)	RANKL/OPG	TNF-𝛼; (pg/mL)	IL-17; (pg/mL)	IL-6; (pg/mL)	IL-4; (pg/mL)
RA patient
Anti-CD3/CD28	100.72 ± 11.98	0.57 ± 0.15	190.24 ± 51.25	508.52 ± 90.94	606.76 ± 49.79	7939.02 ± 2108.85	9.46 ± 4.15
D2M2	91.60 ± 10.47	0.54 ± 0.13	174.64 ± 31.68	294.4 ± 97.24	341.53 ± 58.68	3464.63 ± 2061.39	20.82 ± 13.50
Healthy control
Anti-CD3/CD28	83.09 ± 12.17	0.61 ± 0.07	136.23 ± 13.42	195.95 ± 52.83	249.87 ± 17.63	2607.90 ± 232.98	6.77 ± 4.43
D2M2	70.44 ± 13.01	0.52 ± 0.43	136.28 ± 27.89	151.48 ± 32.21	197.98 ± 43.97	2427.27 ± 238.13	10.73 ± 5.59

Values are expressed as mean ± standard deviation.